Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot
Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot
复制标题
DOI：
10.1097/meg.0000000000001232
复制
发表时间：
2018-10-01
影响因子：
2.1
通讯作者：
Eldars, Waleed
中科院分区：
文献类型：
--
作者：
Abdel-Razik, Ahmed;Mousa, Nasser;Eldars, Waleed
非酒精性脂肪性肝病（NAFLD）的发病机制可能包括胰岛素抵抗增加、促炎细胞因子、脂多糖和BMI的上调。利福昔明是一种吸收最少的抗生素，可能对广谱肠道细菌起作用。本研究旨在调查利福昔明对NAFLD.Patients and MethodsFifty参与者活检证实非酒精性脂肪性肝炎（NASH）的影响，在这个多中心，双盲，随机，安慰剂对照研究中注册。在基线和第1、3、4、5、6、7、8、10、12、14、16、18、19、20、21、22、23、24、26、28、29、2利福昔明组25例，安慰剂组25例。利福昔明治疗6个月后，NASH患者的稳态模型评估、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、谷氨酰转移酶、内毒素、Toll样受体-4、IL-6、肿瘤坏死因子、CK-18和NAFLD-肝脏脂肪评分均显著降低（均P
Background/AimsThe pathogenesis of nonalcoholic fatty liver disease (NAFLD) may include increased insulin resistance, upregulation of proinflammatory cytokines, lipopolysaccharide, and BMI. Rifaximin is a minimally absorbable antibiotic that might act against a broad spectrum of gut bacteria. This study aimed to investigate the effects of rifaximin on NAFLD.Patients and methodsFifty participants with biopsy-proven nonalcoholic steatohepatitis (NASH) were registered in this multicentric, double-blind, randomized, placebo-controlled study. BMI, alanine aminotransferase, aspartate aminotransferase, -glutamyl transferase, lipid profile, serum endotoxin, homeostatic model assessment, toll-like receptor-4, interleukin-10 (IL-10), IL-6, tumor necrosis factor-, and cytokeratin-18 (CK-18) levels were evaluated at baseline and at 1, 3, and 6 months of rifaximin therapy (1100mg/day).ResultsPatients were randomized into two groups (rifaximin group; n=25 and placebo group; n=25). After 6 months of rifaximin therapy, patients with NASH showed a significant reduction in homeostatic model assessment, alanine aminotransferase, aspartate aminotransferase, -glutamyl transferase, endotoxin, toll-like receptor-4, IL-6, tumor necrosis factor-, CK-18, and NAFLD-liver fat score (all P